LAUSR

Burger, J.A., Tedeschi, A., Barr, P.M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N.L., Li, J., Simpson, D., Grosicki, S., Devereux, S., McCarthy, H., Coutre, S., Quach, H., Gaidano, G., Maslyak, Z., Stevens, D.A., Janssens, A., Offner, F., Mayer, J., O’Dwyer, M., Hellmann, A., Schuh, A., Siddiqi, T., Polliack, A., Tam, C.S., Suri, D., Cheng, M., Clow, F., Styles, L., James, D.F. & Kipps, T.J. (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. New England Journal of Medicine, 373, 2425–2437. Byrd, J.C., Brown, J.R., O’Brien, S., Barrientos, J.C., Kay, N.E., Reddy, N.M., Coutre, S., Tam, C.S., Mulligan, S.P., Jaeger, U., Devereux, S., Barr, P.M., Furman, R.R., Kipps, T.J., Cymbalista, F., Pocock, C., Thornton, P., Caligaris-Cappio, F., Robak, T., Delgado, J., Schuster, S.J., Montillo, M., Schuh, A., de Vos, S., Gill, D., Bloor, A., Dearden, C., Moreno, C., Jones, J.J., Chu, A.D., Fardis, M., McGreivy, J., Clow, F., James, D.F. & Hillmen, P. (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New England Journal of Medicine, 371, 213–223. Scheers, E., Leclercq, L., de Jong, J., Bode, N., Bockx, M., Laenen, A., Cuyckens, F., Skee, D., Murphy, J., Sukbuntherng, J. & Mannens, G. (2015) Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an openlabel, phase I, single-dose study in healthy men. Drug Metabolism and Disposition, 43, 289–297. Shanafelt, T.D., Rabe, K.G., Hanson, C.A., Call, T.G., Schwager, S., Parikh, S.A., Nasr, S.H. & Leung, N. (2013) Renal disease in patients with Chronic Lymphocytic Leukemia (CLL). Blood, 122, 5302–5302.